The largest database of trusted experimental protocols

4 protocols using sb 505124

1

Antibody Validation Protocols for Cellular Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following antibodies (Abs) were purchased from Cell Signaling Technology (CST, Danvers, MA, USA): p-SMAD1 (Ser206), p-SMAD2 (Ser465/467), p-SMAD3 (Ser423/425), SMAD2/3, HA-Tag, p-ERK1/2 (Thr202/Tyr204), ERK1/2, p-MAPK14 (Thr180/Tyr182), MAPK14, and p-JNK1/2 (Thr183/Tyr185). Abs against GAPDH, RUNX2, COL10A1, MMP13, SMAD1, SMAD4, ITGB1, JNK1/2, THOC1, p-SMAD1 (Ser463/Ser465), and anti-phospho-serine/threonine antibody were from Abcam (Cambridge, UK). Abs against COL2A1, BMPR1A, and BMPR1B were obtained from Santa Cruz Biotechnology (Dallas, TX, USA). p-ITGB1 (Thr788) and Flag-Tag Abs were obtained from Sigma-Aldrich (St. Louis, MO, USA). Goat anti-rabbit IgG H&L (HRP) and goat anti-mouse IgG H&L (HRP) secondary antibodies were purchased from Thermo Scientific (Waltham, MA, USA). Goat anti-rabbit IgG (H+L), F(ab′)2 fragment (Alexa Fluor® 555 Conjugate) secondary antibodies were from CST. Anti-human IgG antibody was purchased from Abcam.
Blocking antibodies against human integrin beta1, recombinant human interleukin-1 beta, and recombinant human BMP2 were obtained from R&D systems. Purified COL2A1 was purchased from Chondrex, Inc. (Redmond, WA, USA). U0126 and SP600125 were from CST. SB505124 was obtained from MedChemExpress (Monmouth Junction, NJ, USA).
+ Open protocol
+ Expand
2

Transfection Protocols for miRNA and siRNA

Check if the same lab product or an alternative is used in the 5 most similar protocols
Transfection was performed using Lipofectamine 3000 (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. Cells were transfected with miR-1208 mimics, miR-mimic-control, circCREBBP siRNAs, TGFβ2 siRNAs, or si-NC (RiboBio, Guangzhou, China) at 50 nM, whereas miR-1208 inhibitor or inhibitor control (RiboBio) was used at a concentration of 100 nM. The overexpression vector pLC5-circCREBBP was constructed using amplified DNA fragments, including the sequence of full-length human circCREBBP_007 cDNA (713 bp, NM_004380) obtained from Geneseed (Guangzhou, China). Human pGenesil-1-si-h-circCREBBP based on valid siRNA-circCREBBP sequences was purchased from HanBio (Shanghai, China). The specific sequences are listed in Supplementary Table 3. Specific inhibitors of ALK5 (SB-505124, HY-13521, 1 μM) and ALK1 (K02288, HY-12278, 0.5 µM) were purchased from MedChemExpress (Monmouth Junction, NJ, USA).
+ Open protocol
+ Expand
3

Cell Line Cultivation and Inhibitor Treatments

Check if the same lab product or an alternative is used in the 5 most similar protocols
The GH3, AtT20, MMQ, and RC-4BC cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). GH3, AtT20, and MMQ cell line Twere cultured in Ham's F-12 K medium (L450KJ, BasalMedia) supplemented with 2.5% FBS (S615JY, BasalMedia), 15% horse serum (26,050,088, ThermoFisher), and 1% penicillin/streptomycin (C100C5, NCM biotech. RC-4BC cells were cultured in DMEM (L130KJ, BasalMedia) with 10% FBS, 5 ng/ml recombinant rat EGF (ab290070, Abcam), and 1% penicillin/streptomycin. The following inhibitor and recombinant protein were used: recombinant INHBA (C687, Novoprotein), SB-505124 (HY-13521, MedChemExpress), A 83–01 (HY-10432, MedChemExpress), and recombinant human Follistatin (10685-H08H, Sino Biological).
+ Open protocol
+ Expand
4

Microglia Activation and Modulation Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols
Resting microglia consisted of differentiated microglia cultured in neurobasal medium with all added supplements with differentiation factors (IL-34, TGF-β1 and M-CSF) omitted. Proinflammatory 'M1' microglia were stimulated with IL-1β (50 ng/ml), IFN-γ (20 ng/ml) and TNF-α (10 ng/ml) for 24 h. Proregenerative 'M2' microglia were stimulated with IL-4 (40 ng/ml) and IL-13 (40 ng/ml) for 24 h. All stimulatory factors were obtained from PeproTech. For NPCM treatment, microglia were treated with 50% neurobasal medium without differentiation factors and 50% NPCM or NPMM for 24 h unless otherwise indicated. iPSC microglia were treated with 5 μM of the TGF-β receptor type I inhibitor SB-505124 (MedChemExpress, NJ, USA) or 15 μg/ml rabbit anti-human CX3CR1 neutralizing antibody TP-502 (Torrey Pines Biolabs, NJ, USA) for 24 h to inhibit TGF-β and CX3CL1 signaling, respectively. For MSC-NP coculture experiments, MSC-NP cells were added to iPSC microglia in a 1:1 ratio.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!